Mylan Delays Restructuring Amid COVID-19
Follows Postponement Of Merger With Pfizer’s Upjohn Business
Mylan has delayed a major restructuring program ahead of its planned merger with Pfizer’s Upjohn unit due to the impact of the COVID-19 pandemic, which at the same time brought tailwinds for the firm’s first-quarter results.
You may also be interested in...
Viatris Still Exploring Alternatives For Morgantown Plant As Closure Looms
The end of July will bring the closure of Viatris’ Morgantown plant, following years of compliance issues for the once flagship Mylan facility. But the company has revealed that it is still in the process of exploring alternatives for the site outside of Viatris.
Up To 9,000 Jobs At Risk As Viatris Kicks Off $1bn Restructuring Scheme
With a goal of reducing its cost base by at least $1bn by 2024, Viatris has delivered plans to significantly restructure its global manufacturing network. Up to 20% of Viatris’ 45,000-strong workforce could be impacted by the initiative which will see the firm close, divest or downsize 15 of its manufacturing plants around the globe.
Viatris Plots ‘Significant’ Restructuring As Mylan-Upjohn Merger Completes
Nearly 16 months after it was first announced, the $12bn merger of Mylan and Pfizer’s Upjohn has completed, with the resulting company Viatris preparing to unveil restructuring plans by the end of 2020.